OPTIONAL ALL CAPS EYEBROW ONE LINE
ChromoReport Summer 2019 - Utilizing a Risk-Based Approach to Contract Optimization
Despite ongoing efforts to bring new treatments to market the time taken to get a clinical trial up and running hasn’t improved, with research showing that Phase II and III studies now taking a full month longer than the average seen 10 years ago.
Thorny budget and contract negotiations between sites and sponsors/CROs are the single greatest cause of delays in starting clinical trials.
But does it have to be? How could a risk-based management approach be utilized to optimize contracting?
Thorny budget and contract negotiations between sites and sponsors/CROs are the single greatest cause of delays in starting clinical trials.
But does it have to be? How could a risk-based management approach be utilized to optimize contracting?